Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Coronavirus Update: Korea Approval For Nuvaxovid, Japan Filing For Paxlovid

Scrip Team 18 Jan 2022

More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine.

A Deep Dive Into The Game-Changing Drugs For Skin Diseases

Scrip Team 17 Jan 2022

Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.

Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030

Alaric DeArment 10 Jan 2022

CancerCells_Creations_223873720_1200x675

At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.

MIG Capital: BioNTech Has Transformed Global View Of German Biotech 'But We Don’t Walk On Water’

Andrew McConaghie 23 Dec 2021

MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.

Moderna Co-Founder Robert Langer’s Tips For Innovation

Vibha Ravi 22 Nov 2021

Moderna co-founder Robert Langer shared tips to drive innovation at a recent summit, while narrating a fascinating tale of tenacity during the development of angiogenesis inhibitors with Judah Folkman. If an idea is important, it’s sure to be criticized, said the man who has over 1,000 patents issued or pending worldwide.

Scrip

Sofinnova Raises €472m To Build Europe’s Biggest Early-Stage Investment Fund

By Andrew McConaghie 19 Oct 2021

The VC firm is making the most of a surge of capital from new and established investors who believe in the promise of European biopharma start-ups.

Quick Listen: Scrip’s Five Must-Know Things

Ian Haydock 17 Oct 2021

In this week's podcast edition of Five Must-Know Things: US tax policies challenge pharma; J&J’s long-time R&D head to retire; Legend Biotech’s CEO talks about plans; BMS disappointment in ulcerative colitis; and another gene therapy partnership for Takeda.

2020 Deal-Making Roundup

21 Sep 2021

Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.

Quick Listen: Scrip’s Five Must-Know Things

09 Aug 2021

In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.

Quick Listen: Scrip’s Five Must-Know Things

20 Apr 2021

In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.

Pandemic Perspectives: R&D Lessons Learned From The COVID Year

Mary Jo Laffler 17 Mar 2021

The ways companies found to move forward during the challenging year also offer opportunities for industry to improve. During a roundtable discussion with Scrip, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors weighed in on the adaptations they made and what changes they’ll stick with.

2021 Scrip Pharma Trends

25 Feb 2021

For Scrip’s annual preview our journalists asked over 200 industry executives and experts for their predictions of the major trends for 2021. From the pandemic, to AI, therapeutics, and the new US leadership, here’s what to watch out for – in a year with so much at stake.

First In World COVID-19 Vaccine For Kids Below 12?

Vibha Sharma 06 Jan 2021

Could Serum Institute or Bharat Biotech be the first company to have a COVID-19 vaccine for children under 12 years of age? While Pfizer and Moderna have begun pediatric trials for children 12 years and above, Serum plans to begin testing its indigenous vaccine and Bharat Biotech its Covaxin in children under 12

Quick Listen: Scrip's Five Must-Know Things

08 Dec 2020

Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things

Quick Listen: Scrip's Five Must-Know Things

Ian Haydock 29 Nov 2020

Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things